Medical Advocates
Protease Inhibitors
 
Adverse Cardiovascular Events

General Reports
 Atherosclerosis
 Arteriosclerosis
 Coronary Artery Disease
 Carotid Artery Disease
 Myocardial Infarct
 Neuropathy


 
PI Adverse Events Main Page Main New/Newsworthy Home Page
Last Update:  October 18, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

     Journal Papers, Abstracts, and Commentaries
 
 
Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult
spectrum of disease cohort.
Vaughn G, Detels R.
AIDS Care. 2007 Apr;19(4):492-9.
 Abstract 
 
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and
relationship with drug resistance.
 Masquelier B, Pereira E, Peytavin G, et al 
J Clin Virol. 2005 May;33(1):75-8
 Abstract 
 
Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected
patients.
Iloeje U, Yuan Y, L’italien G, et al 
HIV Med. 2005 Jan;6(1):37-44.
 Abstract 

Protease inhibitors and cardiovascular outcomes in patients with HIV-1.
 Holmberg SD, Moorman AC, Williamson JM,
 Lancet 2002 Nov 30;360(9347):1747-8
 Abstract 

Do protease inhibitors increase the risk for coronary heart disease n patients with HIV-1
infection?
 Klein D, Hurley LB, Quesenberry CP Jr, Sidney S.
 J Acquir Immune Defic Syndr 2002 Aug 15;30(5):471-7
 Abstract 

Acute coronary syndromes in patients treated with HIV protease inhibitors
 Barthelemy O, Escaut L, Vayre F, et al
 Presse Med 2002 Mar 2;31(8):343-8
 Abstract 

  
 
     Conference Reports, Abstracts, and Posters
 
Do Different Protease Inhibitors Used for Human Immunodeficiency Virus Have Varying
Effects on Coronary Heart Disease Risk?
E.L. GILLESPIE, C. M. WHITE, C. I. COLEMAN
(45 ICAAC)
 Abstract
 
Protease Inhibitors May be Associated with Oxidative Stress in HIV-Infected Patients
S. PADILLA , E. BERNAL, M. MASIÁ, et al  
(45 ICAAC)
 Abstract
 
Women’s Intragency HIV Study (WIHS): cardiovascular outcomes in women on PI therapy
M Daftary, AP Dutta, Z Xue, et al
(15IAC)
 Abstract
 
POSTER
 Protease Inhibitor Exposure Time and Risk of Cardiovascular Disease in HIV-infected
Patients
U Iloeje, Y Yuan, G L’Italien, et al
 (11 CROI)
 PDF Poster     Abstract
Atherosclerosis
 

     Journal Papers, Abstracts, and Commentaries
 
HIV positive patients treated with protease inhibitors have vascular changes resembling those
observed in atherosclerotic cardiovascular disease.
Lekakis J, Tsiodras S, Ikonomidis I, et al 
Clin Sci (Lond). 2008 Feb 5 ,
Abstract
 
How HIV protease inhibitors promote atherosclerotic lesion formation.
Thomas CM, Smart EJ.
Curr Opin Lipidol. 2007 Oct;18(5):561-5.
Abstract
 
Estrogen receptor-alpha mediated gender differences in atherosclerosis induced by HIV
protease inhibitors.
Allred KF, Smart EJ, Wilson ME.  
J Biol Chem. 2005 Nov 18;
Abstract
 
Cellular mechanisms of insulin resistance, lipodystrophy and atheroscleosis
 induced by HIV protease inhibitors.
Rudich A, Ben-Romano R, Etzion S, Bashan N.
Acta Physiol Scand. 2005 Jan;183(1):75-88.
Abstract

FULL-TEXT ARTICLE
 IV protease inhibitors promote atherosclerotic lesion formation independent of
dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in
macrophages.
 Dressman J, Kincer J, Matveev SV, et al.
J Clin Invest 2003 Feb;111(3):389-97
 Paper

  
Arteriosclerosis
       

     Journal Papers, Abstracts, and Commentaries

 

Impact of Treatment With Protease Inhibitors on Aortic Stiffness in Adult Patients
With Human Immunodeficiency Virus Infection.
Schillaci G, De Socio GV, Pirro M, et al;
 Arterioscler Thromb Vasc Biol. 2005 Aug 25;
 Abstract  

 
Carotid Artery Disease
       

     Journal Papers, Abstracts, and Commentaries

 

3-year Follow-up of Carotid Intima-media Thickness in HIV-infected and Uninfected Adults:
ACTG 5078
J Currier, M Kendall, K Henry, et al
(13 CROI)
 Abstract  

 
     Journal Papers, Abstracts, and Commentaries

Coronary Artery Disease
 
 

Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte
volume in black injection drug users infected with human immunodeficiency virus-1
treated with protease inhibitors.
 Meng Q, Lima JA, Lai H, Vlahov D, et al
 Am Heart J 2002 Oct;144(4):642-8
 Abstract  

Stent Implantation for Acute Left Main Coronary Artery Occlusion in an HIV-Infected
Patient on Protease Inhibitors.
 Boccara F, Teiger E, Cohen A.
J Invasive Cardiol 2002 Jun;14(6):343-6  
Abstract 

  
Myocardial Infarct
       
  Acute myocardial infarct in HIV-positive patients in treatment with protease inhibitors
 Gurgo AM, Massino Ferri F, et al
 Ital Heart J 2001 Nov;2(11 Suppl):1236-9|
 Abstract 
 
     Conference Reports, Abstracts, and Posters
 
Exposure to PI and NNRTI and Risk of Myocardial Infarction: Results from the D:A:D Study
N Friis-Møller, P Reis, W El-Sadr, et al
(13 CROI)
 Abstract
Neuropathy|
 

Journal Papers, Abstracts, and Commentaries
 
  Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency
syndrome patients: Protease inhibitor-mediated neurotoxicity.
Pettersen JA, Jones G, Worthington C, et al 
Ann Neurol. 2006 Apr 21;59(5):816-824
Abstract 

PI Adverse Events Main Page Main New/Newsworthy Home Page

Protease Inhibitors Adverse Cardiovascular Events